QT Imaging Holdings, Inc. (NASDAQ: QTI) is a healthcare technology company headquartered in Novato, California, dedicated to advancing breast health through innovative imaging solutions. The company develops and manufactures sophisticated automated systems, with its flagship product being the QT Ultrasound Breast Scanner. This device provides both reflection-mode and transmission-mode ultrasound ...QT Imaging Holdings, Inc. (NASDAQ: QTI) is a healthcare technology company headquartered in Novato, California, dedicated to advancing breast health through innovative imaging solutions. The company develops and manufactures sophisticated automated systems, with its flagship product being the QT Ultrasound Breast Scanner. This device provides both reflection-mode and transmission-mode ultrasound imaging, offering a radiation-free, comfortable alternative to traditional mammography. The technology leverages quantitative transmission (QT) ultrasound, combined with artificial intelligence and biomarkers, to enable earlier and more accurate detection of breast abnormalities.
Since its establishment in 2011, QT Imaging has focused on improving global health outcomes by making safe, accessible, and cost-effective breast imaging widely available. The company's platform is designed to be patient-first, emphasizing data-driven precision care. In March 2024, QT Imaging completed a business combination with GigCapital and began trading on the NASDAQ under the ticker symbol QTI, providing public market validation and growth capital.
Financially, the company has shown revenue generation with a trailing twelve-month revenue of approximately $22.4 million (derived from revenue per share of $1.642 and share count), but it continues to incur losses, with a net profit margin of -58.9% and negative operating cash flow. The company's financial metrics indicate a relatively high debt-to-equity ratio of 1.528 and a current ratio of 2.486, suggesting liquidity but also reliance on debt. Key executives include CEO Raluca Dinu, who brings extensive international leadership experience, and founder John C. Klock, MD, who serves as a board member.
Looking ahead, QT Imaging aims to expand its market presence, regulatory approvals, and clinical adoption. The company also focuses on research and development (R&D) to enhance its platform, with R&D expenses accounting for 21.2% of revenue. With a small team of 32 employees, QT Imaging operates in a niche but growing market for non-invasive breast imaging, holding potential for significant impact in women's health.
Operator: Welcome to the QT Imaging Second Quarter 26 Financial Results Conference Call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to your host, Bruce Voss. With us on the call today are Dr. Raluca Dinu, Chief Executive Officer and Jay Jennings, Chief Financial Officer. I want to remind listeners that comments made during this call by management will include forward looking statements within the meaning of federal securities laws. Any statements that are not statements of historical facts should be deemed to be forward looking statements. Such statements involve known and unknown risks. Uncertainties and other factors that may cause actual results performance, or achievements to be materially different from those implied by such statements. All forward looking statements are based on QT Imaging's current beliefs, as well as assumptions made by and information currently available to QT imaging. And relate to, among other things, QT imaging breast acoustic CT scanner including its product commercialization and manufacturing, the evolution of QT imaging into a scalable imaging platform, a QTI cloud platform and SaaS model, performance of software enhancements, new product development and introduction, and product sales growth and projected revenues. For a list and description of the risks and uncertainties associated with the company's business, please see its filings with the Securities and Exchange Commission. Furthermore, the content of this call contains information that is accurate only as of the date of this live broadcast, 08/12/2026. QT Imaging disclaims because of new information, future events, or otherwise. Mhmm. And now I would like to turn the call over to Doctor. Raluca Dinu. Raluca?
Raluca Dinu: Thank you, Bruce, and good afternoon, everyone. Thank you for spending time with us and for your interest in QT Imaging. The second quarter was another strong period of execution for QT Imaging as we continued to scale our commercial business and build the foundation for broader adoption of breast acoustic CT imaging technology. Our mission is to transform breast health by giving women and physicians a better approach to breast imaging. Today's pathway still has important limitations. Mammography can be less effective in dense breasts and requires compression. MRI can be costly and burdensome. And conventional ultrasound remains highly operator dependent. CT imaging was built to address these challenges with a differentiated 3-dimensional imaging platform that is radiation free compression free and quantitative. Our vision extends beyond delivering a better imaging experience. We are building a platform designed to provide objective reproducible information that can support …
